

Dispatch of Rights Issue Offer Prospectus

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to confirm that in accordance with the indicative timetable, the Rights Issue Offer Prospectus ("Prospectus") together with the accompanying personalised Entitlement and Acceptance Form, has been dispatched today, Tuesday 27 February 2024.

Shareholders are advised that the Rights Issue Offer under the Prospectus is now open for subscription.

Eligible Shareholders can access their personalised Entitlement and Acceptance forms online at:

<https://investor.automic.com.au/#/home>

Under the Prospectus timetable presented below, the closing date for the Offer is 5.00pm (AEDT) on Thursday, 14 March 2024:

Indicative Rights Issue Offer Timetable ¹ Event	Date
Dispatch of Prospectus and Rights Issue Offer opens	27 February 2024
Closing of Rights Issue Offer	5.00pm 14 March 2024
Allotment and issue of New Shares under Rights Issue Offer	On or before 21 March 2024
Expected normal trading of New Shares under Rights Issue Offer	22 March 2024

- ENDS -

Authorised for release by the Board.

For further information contact us via investor@rhythmbio.com:

Mr. Otto Buttula Executive Chairman	Mr. Guy Carisbrooke Financial Controller	Mr. James Barrie Joint Company Secretary
---	--	--

¹ Dates / times are indicative and subject to change. All times / dates are in reference to Australian Eastern Daylight Time (AEDT)

Directors

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.